International Money (NASDAQ:IMXI) Bolsa

INTERNATIONAL MONEY EXPRESS

IntL Money Express

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

International Money

International Money Express, Inc. - Common Stock

International Money Express Inc

<a href="https://www.globenewswire.com/Tracker?data=Ou9kpYQseMcOTKihNNuPbZdbdUfYNyXJYPkg3pQ3KLwvRZ9k2ky7RIhZaSLxWcu0SRZ9435v_vidgmuJsbcVFQ==">Cemtrex Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>, CETXP))), an advanced security technology and industrial services company, today announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The Company's security will continue to be listed and traded on The Nasdaq Stock Market.
Cemtrex previously received a notification letter from the Nasdaq Listing Qualifications Department on February 21, 2025, notifying the Company that, because the stockholders' equity for the Company was below the minimum required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1).
Based on the Company's Form 10-Q filed on May 15, 2025, evidencing stockholders' equity of $6,403,022, Nasdaq has determined that the Company complies with the Minimum Stockholder's Equity Requirement and this matter is now closed.

News

CETX

Cemtrex Regains Compliance With Nasdaq Requirements

- Crown Electrokinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) ("Crown" or the "Company"), a leader in optical and fiber infrastructure solutions, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Crown EK Acquisition LLC ("Parent") and Crown EK Merger Sub Corp. ("Purchaser"), a wholly owned subsidiary of Parent.
Parent is controlled by Douglas Croxall, the Company's Chairman and Chief Executive Officer. Under the terms of the Merger Agreement, Purchaser will commence a tender offer to acquire all outstanding shares of Crown's common stock for a cash purchase price of&nbsp;$3.15 per share, subject to the terms and conditions of the Merger Agreement.
The proposed transaction has been unanimously approved by a special committee (the "Special Committee") comprised of independent directors of Crown's board of directors and is intended to result in Crown becoming a wholly owned subsidiary of Parent. The Special Committee received a fairness opinion from an independent financial advisor and determined the transaction is fair to, and in the best interests of, Crown's unaffiliated public stockholders.

CRKN

Crown Electrokinetics Enters Merger Agreement To Be Acquired For $3.15/Share In All-Cash Tender Offer Led By CEO-Controlled Entity

AVITA Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>, ASX: AVH))), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted data presented by researchers at the British Burn Association (BBA) Annual Meeting demonstrating reduced length of hospital stay among burn patients treated with RECELL&#xAE;. The session, titled The Clinical Impact of Skin Cell Suspension Autograft from a National Registry Perspective, represents the largest real-world analysis of skin cell suspension autograft (commercially known as RECELL) to date.
The patented RECELL technology uses a small sample of a patient's own skin to produce Spray-On Skin&#x2122; Cells, an autologous cell suspension that supports wound healing throughout the wound bed. Compared to traditional skin grafting, RECELL requires significantly less donor skin and offers a range of clinical benefits, including less pain at the donor site, faster healing, improved outcomes, and fewer procedures. These advantages contribute to shorter hospital stays and associated cost savings.

RCEL

AVITA Medical Highlights Data Presented By Researchers At BBA Annual Meeting Demonstrating Reduced Length Of Hospital Stay Among Burn Patients Treated With RECELL

<a href="https://www.globenewswire.com/Tracker?data=eN_cNwMUHBrO7JVYrXXbNkM34zP9UAqvLf5PT22uOnq-CPcHv7vFjW2A0nk9eMA-WfTZQHiF3jxBfz9UPNz0IJTrLxNh245wz6LxkUqsxHyenU6zxXkieFaJVxweSflwLPCsP3kpFYclXrCmCgr0uXk28gHy_rqjYA1CnEEVQ7kkg8W4QkCk1KcJWoUGBYK1tGnfTlTJrFH8M-DFh0i2p4T2ZXxFxRqwvND9JPCO5TyhLh8cxZ806F51z_I95ccGqtU3btE2U20_Lxk0bzgYyw==">ReShape Lifesciences</a>&#xAE;("ReShape" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>),&nbsp;the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6 million before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as sole placement agent in connection with the offering.

Offerings

RSLS

ReShape Lifesciences Prices $2.6M Public Offering Of 1,054,604 Shares At $2.50 Per Share

CBAK Energy Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) ("CBAK Energy," or the "Company"), a leading lithium-ion battery manufacturer and electric energy solution provider in&nbsp;China, today announced that its wholly-owned subsidiary, Nanjing CBAK New Energy Technology Co., Ltd. ("Nanjing CBAK"), has received a sizeable order from Africa's largest EV player with the fastest energy distribution network aided by battery swapping.
The order, valued at approximately US$11.6 million, primarily comprises CBAK Energy's advanced Model 32140 large LFP cylindrical batteries. Looking ahead, the Company anticipates follow-on orders from this customer totaling up to US$55 million. As part of this strategic partnership, CBAK Energy will continue to supply its high-performance Model 32140 batteries for integration into the customer's rapidly expanding fleet of electric motorcycles across the African continent. This collaboration underscores a shared commitment to accelerating the adoption of sustainable mobility solutions in emerging markets.

CBAT

CBAK Energy Technology's Subsidiary, Nanjing CBAK, Bags $11.6M Order From Africa's EV Player

Earnings

Earnings Beats

CORRECTION: Genesco Reported On June 4th, Q1 Adj. EPS $(2.05) Beats $(2.09) Estimate, Sales $473.97M Beat $465.30M Estimate

ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $149.73, a high estimate of $180.00, and a low estimate of $115.00. This current average represents a 15.31% decrease from the previous average price target of $176.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1749474061_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of ARM Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ananda Baruah</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$155.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Gardiner</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Srini Pajjuri</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$203.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$144.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Lee Simpson</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ARM Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ARM Holdings compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ARM Holdings's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ARM Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ARM Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind ARM Holdings</h2>
Arm Holdings is the intellectual property owner and developer of the ARM architecture, which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allow them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Both off-the-shelf and architectural customers pay a royalty fee per chip shipped.
<h3>ARM Holdings: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: ARM Holdings's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 33.73%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ARM Holdings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 3.17%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.41%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About ARM Holdings Stock

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target of $180.36, a high estimate of $216.00, and a low estimate of $150.00. Witnessing a positive shift, the current average has risen by 0.95% from the previous average price target of $178.67.
<img src="https://www.benzinga.com/files/images/story/2025/1749474050_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$150.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Matthew Hershenhorn</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Axsome Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Discovering Axsome Therapeutics: A Closer Look</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 61.95%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -48.91%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -107.81%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews

12 analysts have expressed a variety of opinions on Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Fifth Third Bancorp and provided 12-month price targets. The average target is $46.25, accompanied by a high estimate of $52.00 and a low estimate of $42.00. A decline of 7.67% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749474041_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Fifth Third Bancorp by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Foran</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Vivek Juneja</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fifth Third Bancorp. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Fifth Third Bancorp compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fifth Third Bancorp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FITB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Fifth Third Bancorp analyst ratings.</a>
<h2>Delving into Fifth Third Bancorp's Background</h2>
Fifth Third Bancorp is a diversified financial-services company headquartered in Cincinnati. The company has over $210 billion in assets and operates numerous full-service banking branches and ATMs throughout Ohio, Kentucky, Indiana, Michigan, Illinois, Florida, Tennessee, West Virginia, Georgia, and North Carolina.
<h3>Fifth Third Bancorp: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Fifth Third Bancorp displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.71%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 22.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.67%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Fifth Third Bancorp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.22%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Fifth Third Bancorp's debt-to-equity ratio is below the industry average. With a ratio of 1.08, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FITB

Deep Dive Into Fifth Third Bancorp Stock: Analyst Perspectives (12 Ratings)

Monolithic Power Systems's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NYSE">MPWR</a>) short percent of float has risen 21.01% since its last report. The company recently reported that it has 2.45 million shares sold short, which is 6.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.81 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Monolithic Power Systems Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749474035_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Monolithic Power Systems has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Monolithic Power Systems's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Monolithic Power Systems's peer group average for short interest as a percentage of float is 5.54%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MPWR

Is the Market Bullish or Bearish on Monolithic Power Systems?

Cogent Comms Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NYSE">CCOI</a>) short percent of float has fallen 6.05% since its last report. The company recently reported that it has 4.17 million shares sold short, which is 12.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Cogent Comms Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749474029_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cogent Comms Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cogent Comms Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Cogent Comms Hldgs's peer group average for short interest as a percentage of float is 5.79%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CCOI

Looking Into Cogent Comms Hldgs's Recent Short Interest

<a target="_blank" href="https://www.benzinga.com/topic/cryptocurrencies" rel="noreferrer noopener">Cryptocurrency exchange</a> Kraken on Monday announced a strategic partnership with Alpaca, a brokerage infrastructure API and self-clearing broker-dealer offering equities, options, fixed income, and crypto trading.
Through this partnership, Alpaca expanded its regulated crypto spot and derivatives trading capabilities by incorporating Kraken Embed, Kraken&#8217;s Crypto-as-a-Service (CaaS) solution.
The enhancement provides Alpaca&#8217;s more than 200 enterprise partners with seamless access to hundreds of cryptocurrencies powered by Kraken&#8217;s global and institutional-grade infrastructure through Alpaca&#8217;s unified Broker API.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/03/44416968/kraken-to-buy-ninjatrader-for-1-5-billion-entering-us-crypto-futures-market-in-2025" rel="noreferrer noopener">Kraken To Buy NinjaTrader For $1.5 Billion, Entering US Crypto Futures Market In 2025</a>
Brett McLain, Head of Payments and Blockchain at Kraken said that with Kraken Embed, financial institutions could offer compliant end-to-end crypto solutions without the burden of managing complex infrastructure, making it faster and easier to meet growing user demand.
Kraken&#8217;s liquidity and global network of regulatory licenses provide Alpaca&#8217;s partners with access to robust markets and efficient execution, the company said.
Combined with Alpaca&#8217;s regulatory licensing and infrastructure, the partnership delivers a full-service solution for multi-asset trading that enables clients to integrate equities and crypto into their apps with minimal engineering effort.
This partnership is currently live in the United States and plans to expand to Canada, the European Union, and the United Kingdom in the near future. The roadmap also includes additional offerings, such as staking and crypto derivatives, supporting the needs of a growing user base for cryptocurrencies.
Kraken, legally registered as&nbsp;Payward Inc., is reportedly <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/03/44217932/crypto-exchange-kraken-sets-sights-on-2025-initial-public-offering" rel="noreferrer noopener">preparing to go</a> public via an initial public offering as early as the first quarter of next year.
The company&#8217;s revenue more than doubled in 2024, reaching $1.5 billion, with adjusted earnings of $380 million. Since its founding in 2011, Kraken has raised approximately $27 million in primary funding.
Under the Trump administration, the regulatory environment has shifted, creating new opportunities for crypto firms.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45571765/kraken-to-launch-247-tokenized-stock-trading-for-global-users-via-solana" target="_blank" rel="noreferrer noopener">Kraken To Launch 24/7 Tokenized Stock Trading For Global Users Via Solana</a></li>
</ul>
Photo Courtesy: alfernec via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

HODL

IBIT

Kraken Partners With Alpaca To Expand Crypto Trading To Financial Institutions

Analysts' ratings for Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $141.5, a high estimate of $160.00, and a low estimate of $120.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.71%. 
<img src="https://www.benzinga.com/files/images/story/2025/1749474025_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Quaker Houghton's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laurence Alexander</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Harrison</td>
<td>Seaport Global</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Quaker Houghton. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quaker Houghton compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Quaker Houghton's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Quaker Houghton's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KWR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Quaker Houghton analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Quaker Houghton Better</h2>
Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.
<h3>Quaker Houghton: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Quaker Houghton's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -5.71% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Quaker Houghton's net margin is impressive, surpassing industry averages. With a net margin of 2.91%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Quaker Houghton's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.94%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.49%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.55, Quaker Houghton adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Quaker Houghton: What You Need To Know

Genuine Marketing Group Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GMGZ#OTC">GMGZ</a>) announced the beta launch of its blockchain-based platform ZPTAG for the cannabis industry, partnering with Ignite Dispensary to pilot the technology across select locations in Wisconsin.
The announcement was made Monday morning during the <a href="https://www.benzinga.com/cannabis-conference">Benzinga Cannabis Capital Conference</a> in Chicago, one of the industry's leading gatherings of investors, operators and executives.
Beginning June 20, the beta program will cover nine SKUs, including pre-rolls, gummies and infused snack mixes, all tagged with unique identifiers enabling full lifecycle tracking. The ZPTAG platform provides seed-to-sale transparency, offering real-time access to product certifications, lab results and logistics milestones through a mobile application.
According to GMGZ, the system is designed to support government compliance while enhancing supply chain visibility and building consumer trust. It expands upon the company's prior work in Carbon Intensity (CI) scoring and now applies similar principles to reward responsible operators in the regulated cannabis space.
"We are pleased to be launching our cannabis efforts with Ignite Dispensary and working closely with our longtime partner and industry expert, Tim Frey," said Chuck Chastain, CEO of Genuine Marketing Group. "His attention to detail and wealth of cannabis knowledge is indispensable for GMG. I can't think of a better way to ensure ZPTAG delivers for the industry."
Ignite Dispensary founder Timothy Frey said the partnership reflects his company's commitment to transparency and consumer confidence. "ZPTAG lets us take that to the next level by giving you an easy way to see exactly what you are getting and why we stand behind it," said Frey. "It is just one more way we are working to elevate the experience and continue building trust with our community."
The beta will initially launch across Ignite's Wisconsin operations, with plans to expand to other hemp-derived and cannabis products, including THC-infused beverages, tinctures and flower. A broader national rollout is expected in late 2025 and early 2026.
Photo: Shutterstock

Cannabis

Exclusives

Tech

GMGZ

Cannabis Transparency Gets Boost With GMGZ's Blockchain Beta

Selective Insurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NYSE">SIGI</a>) short percent of float has risen 14.29% since its last report. The company recently reported that it has 1.67 million shares sold short, which is 3.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Selective Insurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749474024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Selective Insurance Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Selective Insurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Selective Insurance Gr's peer group average for short interest as a percentage of float is 2.50%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SIGI

Looking Into Selective Insurance Gr's Recent Short Interest

Subsidiary Sovereign Insurance also leveraging ClaimCenter for claims management
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cooperators.ca%2F&amp;esheet=54264597&amp;newsitemid=20250609159651&amp;lan=en-US&amp;anchor=Co-operators&amp;index=1&amp;md5=abac5c84cf65783688ed12f8ee1248bf">Co-operators</a>, a leading Canadian multi-line insurance and financial services organization, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2F&amp;esheet=54264597&amp;newsitemid=20250609159651&amp;lan=en-US&amp;anchor=Guidewire&amp;index=2&amp;md5=0e0ff1a72aacdd19394c597be7363c5e">Guidewire</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) announced that Co-operators successfully implemented <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2Fproducts%2Fclaimcenter%2F&amp;esheet=54264597&amp;newsitemid=20250609159651&amp;lan=en-US&amp;anchor=Guidewire+ClaimCenter&amp;index=3&amp;md5=ebce8c86b4b079b695c44fb26c751b0a">Guidewire ClaimCenter</a> on <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.guidewire.com%2Fproducts%2Fcloud%2F&amp;esheet=54264597&amp;newsitemid=20250609159651&amp;lan=en-US&amp;anchor=Guidewire+Cloud+Platform&amp;index=4&amp;md5=94a453da6fb1f2b816654eecc9d25fc5">Guidewire Cloud Platform</a> to power its claims management functions, adapt to changing market demands, and deliver more value to policyholders.

GWRE

Co-Operators Implements Guidewire ClaimCenter On Guidewire Cloud Platform To Power Claims Management Functions

Lake Street analyst Ryan Meyers initiates coverage on Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) with a Buy rating and announces Price Target of $14.

Price Target

Initiation

SKYH

Lake Street Initiates Coverage On Sky Harbour Group with Buy Rating, Announces Price Target of $14

Barclays analyst Brandon Oglenski initiates coverage on Ryder System (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) with a Overweight rating and announces Price Target of $190.

Barclays Initiates Coverage On Ryder System with Overweight Rating, Announces Price Target of $190

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions.
The double-blind trial of 798 patients achieved statistical significance across all endpoints, demonstrating a 38% reduction in the primary composite endpoint and a remarkable 58% reduction in SSI rates from 9.5% to 3.8% compared to standard care alone.
These results position D-PLEX100 among the most effective prophylactic interventions for this indication, addressing a significant unmet medical need that costs the U.S. healthcare system up to $10 billion annually.
With FDA Fast Track, Breakthrough Therapy, and QIDP designations already secured, PolyPid plans a pre-NDA meeting by end-2025 followed by NDA submission in early 2026, while these compelling Phase 3 results are expected to accelerate ongoing global partnership discussions for commercialization.

PYPD

Polypid Announces Results From SHIELD II Phase 3 Trial Of D-PLEX100 For Preventing SSIs In Abdominal Colorectal Surgery Patients With Large Incisions

WIIM

VinFast Auto shares are trading higher after the company reported better-than-expected Q1 sales results and a year-over-year increase in Q1 EV and E-scooter deliveries.

Comments

International Money

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL